Probiotic Lactoferrin Composition for Antibiotic-Free GBS Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Group-B Streptococcus (GBS) infections during and after pregnancy rely heavily on antibiotics, which are not ideal due to potential side effects and the lack of a vaccine, necessitating an alternative preventive and curative approach.
Innovation Solution
A composition comprising Lactobacillus acidophilus, Lactobacillus rhamnosus, and lactoferrin is used to inhibit GBS growth, leveraging their synergistic effects to prevent and treat GBS infections without antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic therapy is used to treat GBS infections, then the effectiveness against pathogen is improved, but the harmful side effects and resistance issues worsen
Solution Approach 1:
The patent uses lactobacilli strains (L. acidophilus and L. rhamnosus) as intermediary organisms that produce antimicrobial substances to inhibit GBS growth. These probiotic bacteria act as mediators between the host immune system and the pathogen, providing therapeutic effect without direct use of antibiotics. The lactobacilli colonize the vaginal tract and continuously produce inhibitory substances against GBS.
Solution Approach 2:
The invention combines multiple components in a composite formulation: two different lactobacillus strains (L. acidophilus and L. rhamnosus) with distinct antimicrobial mechanisms, plus lactoferrin as an additional antimicrobial agent. This composite approach synergistically enhances GBS inhibition while maintaining safety, as each component contributes different mechanisms of action against the pathogen.
2Reliability
If a vaccine is developed for GBS prevention, then the long-term protection is improved, but the current lack of vaccine necessitates alternative approaches
Solution Approach 1:
The patent implements preliminary action by administering lactobacilli strains to pregnant women before delivery and to newborns immediately after birth. This early colonization establishes protective bacteria in the vaginal and gastrointestinal tracts before GBS infection can occur, providing immediate rather than long-term delayed protection. The probiotics are introduced in advance to prevent infection rather than treat it later.
3Reliability
If asymptomatic colonization is detected and treated with antibiotics, then the risk of infection is reduced, but the overuse of antibiotics worsens resistance problems
Solution Approach 1:
The patent replaces antibiotics with lactobacilli strains as intermediary organisms that naturally inhibit GBS through antimicrobial substance production. These probiotic bacteria colonize the vaginal tract and provide continuous protection against GBS without the harmful effects of antibiotic overuse. The lactobacilli serve as a safe, natural alternative that reduces GBS risk while avoiding resistance development.
Solution Approach 2:
The invention changes the therapeutic parameter from chemical antibiotics to biological probiotic organisms. By shifting from small-molecule antibiotics to living lactobacillus cells that produce antimicrobial peptides and organic acids, the treatment mechanism changes fundamentally. This parameter change maintains effectiveness while eliminating the resistance problem associated with conventional antibiotics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of Lactobacillus strains with lactoferrin demonstrates significant and early inhibition of GBS growth, providing a potential alternative to antibiotic therapy, as shown by in vitro studies and ongoing clinical trials.
Implementation Method 1
Lactobacillus acidophilus and Lactobacillus rhamnosus, alone or in combination, and in the presence or absence of Lf, on the growth and proliferation of GBS
Implementation Method 2
Lactoferrin (Lf) is a safe, natural component of most exocrine biological fluids
Data Source
AI summary
The present invention concerns the field of bacterial infections, and in particular Group-B Streptococcus (GBS) infections during and after pregnancy. The present invention relates to the use of a composition comprising a strain of Lactobacillus acidophilus, a strain of Lactobacillus rhamnosus, and lactoferrin in the preventive and/or curative treatment of Group-B Streptococcus (GBS) infections.